Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: SMALL FRY who wrote (35027)	4/20/1999 11:39:00 AM
From: Ryan Mak	Read Replies (2) \| Respond to of 120523

Sf ... I hear you. I am still bleeding but is on the right path to recover!! R

To: SMALL FRY who wrote (35027)	4/20/1999 11:41:00 AM
From: Susan G	Read Replies (1) \| Respond to of 120523

SF - any idea what caused VRIO to break out?

To: SMALL FRY who wrote (35027)	4/20/1999 2:24:00 PM
From: kha vu	Respond to of 120523

cholesterol: good news for AVAN investors and consumers. Monday April 19, 8:05 pm Eastern Time Vaccine may work against heart disease - company WASHINGTON, April 19 (Reuters) - A vaccine that raises levels of so-called ''good'' cholesterol in rabbits may work to prevent heart disease, researchers said on Monday. Scientists at Avant Immunotherapeutics, Inc. (AVAN - news) said their vaccine raised high-density lipoprotein (HDL or ''good'' cholesterol) by 35 percent in rabbits, and reduced the number of artery-blocking plaques by 40 percent. ''We are very pleased with these results, which clearly demonstrate the feasibility of our vaccine approach as a novel strategy for preventing or treating atherosclerosis,'' Una Ryan, president and chief executive officer of the Needham, Massachusetts-based company, said in a statement. ''As a result, we are preparing to initiate human clinical safety studies with the vaccine this summer.'' Atherosclerosis is a form of arteriosclerosis, an abnormal thickening and loss of elasticity of the walls of the arteries. It often accompanies old age. Avant's Lawrence Thomas told a meeting of the Federation of American Societies for Experimental Biology (FASEB) in Washington that the vaccine produces antibodies that block the activity of a compound known as cholesteryl ester transfer protein (CETP). CETP affects the movement of cholesterol from the HDL form, in which it is carried away from arteries, to the low density lipoprotein (LDL or ''bad'' cholesterol) version, in which it is deposited in arteries. High levels of LDL are a big risk factor for atherosclerosis and heart disease. People with higher levels of HDL have a lower risk. Thomas's team used rabbits fed high-fat diets. Many heart disease researchers use such rabbits, as they very easily develop the blockages associated with heart disease. But animal findings do not always carry over into humans. More Quotes and News: Avant Immunotherapeutics Inc (Nasdaq:AVAN - news) Related News Categories: health, US Market News